Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 7:20 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.57 USD
+1.27 (2.87%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $45.60 +0.03 (0.07%) 7:20 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off
by Zacks Equity Research
This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.
Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ
by Urmimala Biswas
Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.
Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.
Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences
by Zacks Equity Research
Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences
4 Best-Ranked Liquid Stocks for Alluring Returns
by Zacks Equity Research
Four top-ranked liquid stocks that investors can bank on for fat returns.
Should You Buy Tandem Diabetes Care (TNDM) Ahead of Earnings?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
5 Top-Ranked Stocks Beating the Market at Midway Q1
by Sweta Killa
Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.
5 High-Flying Stocks Set to Beat on Q4 Earnings Next Week
by Nalak Das
Fourth-quarter 2019 earnings results have been improving significantly.
What's in Store for SmileDirectClub's (SDC) Q4 Earnings?
by Zacks Equity Research
SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.
Tandem Diabetes Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.
Are Options Traders Betting on a Big Move in Tandem Diabetes (TNDM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.
InMode (INMD) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
Will Tandem Diabetes Care Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tandem Diabetes.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.